Evidence map›Paper›PMID 26440629›Full record

ArticlePloS one2015

Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis.

Jacob Sode, Ulla Vogel, Steffen Bank, Paal Skytt Andersen, Merete Lund Hetland, Henning Locht, Niels H H Heegaard, Vibeke Andersen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Pharmacogenomics of TNF inhibitors.Frontiers in immunology · 2025
    Review
  6. Article
  7. Article
  8. Clinical Value ofJournal of personalized medicine · 2022
    Article
  9. Role ofPharmaceutics · 2022
    Article
  10. Review
  11. Article
  12. Pharmacogenetics of Drug Therapies in Rheumatoid Arthritis.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  13. Cell-Free DNA in Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Cyclin Y Modulates the Proliferation, Invasion, and Metastasis of Hepatocellular Carcinoma Cells.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Jacob SodeDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark; Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark; Institute of Regional Health Research-Center Sønderjylland, University of Southern Denmark, Odense, Denmark; OPEN (Odense Patient data Explorative Network), Odense University Hospital, Odense, Denmark.
Ulla VogelNational Research Centre for the Working Environment, Copenhagen, Denmark.
Steffen BankDepartment of Medicine, Viborg Regional Hospital, Viborg, Denmark; Biomedicine, University of Aarhus, Aarhus, Denmark.
Paal Skytt AndersenDepartment of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark; Veterinary Disease Biology, University of Copenhagen, Copenhagen, Denmark.
Merete Lund HetlandThe DANBIO Registry, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Henning LochtDepartment of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark.
Niels H H HeegaardDepartment of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark; Clinical Biochemistry, Clinical Institute, University of Southern Denmark, Odense, Denmark.
Vibeke AndersenInstitute of Regional Health Research-Center Sønderjylland, University of Southern Denmark, Odense, Denmark; Department of Medicine, Viborg Regional Hospital, Viborg, Denmark; Molecular Diagnostic and Clinical Research Unit, Hospital of Southern Jutland, Aabenraa, Denmark; OPEN (Odense Patient data Explorative Network), Odense University Hospital, Odense, Denmark.
Frederiksberg Hospital · DKAarhus University · DKNational Research Centre for the Working Environment · DKOdense University Hospital · DKRigshospitalet · DKStatens Serum Institut · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine whether genetic variation within genes related to the Toll-like receptor, inflammasome and interferon-γ pathways contributes to the differences in treatment response to tumour necrosis factor inhibitors (anti-TNF) in patients with rheumatoid arthritis (RA).

methodsIn a retrospective case-case study, we assessed 23 functional single nucleotide polymorphisms (SNPs) in 15 genes. We included 538 anti-TNF naïve Danish RA patients from the nationwide DANBIO database. Multivariable logistic regression analyses were performed to detect associations (p-value<0.05) between genotypes and European League Against Rheumatism (EULAR) treatment responses. False Discovery Rate corrections for multiple testing (q-value) and stratified analyses were performed to investigate association with individual therapies and IgM-rheumatoid factor (RF) status.

resultsSix of twenty successfully genotyped polymorphisms were nominally associated with EULAR treatment response. Three of these were in weak to moderate linkage disequilibrium with polymorphisms previously reported associated with anti-TNF treatment response. TLR5(rs5744174) variant allele carriers (odds ratio(OR) = 1.7(1.1-2.5),p = 0.010,q = 0.46) and TLR1(rs4833095) homozygous variant carriers (OR = 2.8(1.1-7.4),p = 0.037,q = 0.46) had higher odds for a positive treatment response. NLRP3(rs10754558) variant allele carriers (odds ratio(OR) = 0.6(0.4-1.0),p = 0.045,q = 0.46) were more likely to have a negative treatment response. The association in TLR5(rs5744174) remained significant after correction for multiple comparisons among patients negative for RF (OR = 6.2(2.4-16.3),p = 0.0002,q = 0.024). No other association withstood correction for multiple testing. Post hoc analyses showed that change in Patient Global score on a visual analogue scale (VAS) and change in pain VAS were the main factors responsible for the association.

conclusionsWe reproduced previously reported associations between genetic variation in the TLR10/1/6 gene cluster, TLR5, and NLRP3 loci and response to anti-TNF treatment in RA. Changes in VAS pain and patient global scores were the main contributors to the association found for TLR5. Furthermore, we identified other candidate genes that require replication in independent cohorts.

Indexed as

Polymorphism, Single NucleotideAdalimumabAdaptor Proteins, Signal TransducingAdultAgedAllelesAntirheumatic AgentsApoptosis Regulatory ProteinsArthritis, RheumatoidEtanerceptFemaleGene FrequencyGenetic Association StudiesGenetic LociHumansInflammasomesAdalimumabAdaptor Proteins, Signal TransducingAntirheumatic AgentsApoptosis Regulatory ProteinsEtanerceptInflammasomesInfliximabInterferon-gammaNLRP1 protein, humanNLR ProteinsToll-Like Receptors

Identifiers

PMID26440629
PMCPMC4595012
OpenAlexW1865497936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.